|Bid||50.38 x 900|
|Ask||50.45 x 800|
|Day's range||50.37 - 51.55|
|52-week range||46.41 - 119.81|
|Beta (5Y monthly)||0.40|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Thank you operator and welcome all to the audio webcast of Galapagos Q3 2021 results. The Q3 webcast is accessible on the Galapagos website homepage and will be available for download and replay later on today.
Galapagos (GLPG) finishes enrollment in phase III study evaluating filgotinib for Crohn's Disease. The company also assumes sole responsibility for the DIVERSITY study.
GLPG earnings call for the period ending June 30, 2021.